Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia, Multicenter, Open-label Study of ILB2109 in Patients With Advanced Solid Malignancies

NCT05278546 is registered in ClinicalTrials.gov with Innolake Biopharm as lead sponsor.

NCT NCT05278546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05278546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia, Multicenter, Open-label Study of ILB2109 in Patients With Advanced Solid Malignancies
Lead sponsor
Innolake Biopharm
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 11, 2022
Completion date
February 28, 2025
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor